Acetyllcarnitine for dementia
In the SURMOUNT-1 trial, 95 percent of participants taking tirzepatide reverted to normal blood sugar over 176 weeks, and 99 percent stayed diabetes-free
This is a challenging target for many individuals, especially those with a suppressed appetite and likely reduced caloric intake
Across cohorts, 48 weeks of retatrutide reduced liver fat by 50% or greater in 43-100% of participants and 70% or greater in 22-86%
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...' Big pharma is currently facing a potential "bubble effect" due to the surging demand for weight loss and diabetes drugs, as revealed in a report by Deloitte released on Monday
Week 0: Intake Intake questionnaire